The contribution of specific class I and II histone deacetylases in the development of anxietyrelated behavior in a mouse model of prenatal immune challenge
AbstractSeveral lines of evidence demonstrated that maternal infection during gestation might be an environmental risk factor for offspring to develop mood and anxiety disorders later in life. Previous experiments revealed that anxiety-related behavior, observed after prenatal immune challenge, is associated with increased histone deacetylase (HDAC) activity in adult female mice. Based on these findings, this study aims to investigate which class I and II HDAC isotypes might be involved in the development of the long-lasting consequences of prenatal immune challenge. Therefore, pregnant C57BL/6JRccHsd inbred mice were intravenously injected with poly I:C (5 mg/kg bodyweight) at gestational day (GD) 17 to mimic a viral infection. Brains from adult offspring were homogenized and used for western blotting to analyse the relative protein levels of HDAC1, 2, 3, 4, 5 and 6. Due to a lack of signal in HDAC1, HDAC3 and HDAC5, an irregular signal in HDAC2, and a weak signal in HDAC4 and HDAC6, the quality of the western blots was insufficient for protein quantification. Therefore, no subsequent comparison could be made between mice exposed to prenatal poly I:C and PBS in the current study
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005;62(6):593.
Association AP. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition Arlington, VA: American Psychiatric Association; 2013. 155-88 p.
Gorman JM. Comorbid depression and anxiety spectrum disorders. Depress Anxiety. 1996;4(4):160-8.
Berton O, Nestler EJ. New approaches to antidepressant drug discovery: beyond monoamines. Nat Rev Neurosci. 2006;7(2):137-51.
Massart R, Mongeau R, Lanfumey L. Beyond the monoaminergic hypothesis: neuroplasticity and epigenetic changes in a transgenic mouse model of depression. Phil Trans R Soc B. 2012;367(1601):2485-94
Young SN, Smith SE, Pihl RO, Ervin FR. Tryptophan depletion causes a rapid lowering of mood in normal males. Psychopharmacology. 1985;87(2):173-7.
Mellor AL, Munn DH. Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation? Immunol Today. 1999;20(10):469-73.
Myint A-M, Kim YK, Verkerk R, Scharpé S, Steinbusch H, Leonard B. Kynurenine pathway in major depression: evidence of impaired neuroprotection. J Affect Disord. 2007;98(1):143-51.
Fukui S, Schwarcz R, Rapoport SI, Takada Y, Smith QR. Blood–brain barrier transport of kynurenines: implications for brain synthesis and metabolism. J Neurochem. 1991;56(6):2007-17.
Heyes M, Achim C, Wiley C, Major E, Saito K, Markey S. Human microglia convert l-tryptophan into the neurotoxin quinolinic acid. Biochem J. 1996;320:595-7.
Myint AM. Kynurenines: from the perspective of major psychiatric disorders. FEBS J. 2012;279(8):1375-85.
Okuda S, Nishiyama N, Saito H, Katsuki H. 3-Hydroxykynurenine, an endogenous oxidative stress generator, causes neuronal cell death with apoptotic features and region selectivity. J Neurochem. 1998;70(1):299-307.
Wu H-Q, Guidetti P, Goodman J, Varasi M, Ceresoli-Borroni G, Speciale C, et al. Kynurenergic manipulations influence excitatory synaptic function and excitotoxic vulnerability in the rat hippocampus in vivo. Neuroscience. 2000;97(2):243-51.
Perkins M, Stone T. An iontophoretic investigation of the actions of convulsant kynurenines and their interaction with the endogenous excitant quinolinic acid. Brain Res. 1982;247(1):184-7.
Guillemin GJ, Kerr SJ, Smythe GA, Smith DG, Kapoor V, Armati PJ, et al. Kynurenine pathway metabolism in human astrocytes: a paradox for neuronal protection. J Neurochem. 2001;78(4):842-53.
Wichers MC, Koek G, Robaeys G, Verkerk R, Scharpé S, Maes M. IDO and interferon-α-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity. Mol Psychiatry. 2004;10(6):538-44.
Stiles J, Jernigan TL. The basics of brain development. Neuropsychol Rev. 2010;20(4):327-48.
Markham JA, Koenig JI. Prenatal stress: role in psychotic and depressive diseases. Psychopharmacology. 2011;214(1):89-106.
Canetta SE, Brown AS. Prenatal infection, maternal immune activation, and risk for s chizophrenia. Transl Neurosci. 2012;3(4):320-7.
Howerton CL, Bale TL. Prenatal programing: at the intersection of maternal stress and immune activation. Horm Behav. 2012;62(3):237-42.
Gilmore JH, Jarskog LF, Vadlamudi S, Lauder JM. Prenatal infection and risk for schizophrenia: IL-1b, IL-6, and TNFa inhibit cortical neuron dendrite development. Neuropsychopharmacol. 2004;29:1221-9.
Jarskog LF, Xiao H, Wilkie MB, Lauder JM, Gilmore JH. Cytokine regulation of embryonic rat dopamine and serotonin neuronal survival in vitro. Int J Dev Neurosci. 1997;15(6):711-6.
Jaenisch R, Bird A. Epigenetic regulation of gene expression: how the genome integrates intrinsic and environmental signals. Nat Genet. 2003;33:245-54.
Kouzarides T. Chromatin modifications and their function. Cell. 2007;128(4):693-705.
Tsankova N, Renthal W, Kumar A, Nestler EJ. Epigenetic regulation in psychiatric disorders. Nat Rev Neurosci. 2007;8(5):355-67.
Abel T, Zukin RS. Epigenetic targets of HDAC inhibition in neurodegenerative and psychiatric disorders. Curr Opin Pharmacol. 2008;8(1):57-64.
MacPhee DJ. Methodological considerations for improving Western blot analysis. J Pharmacol Toxicol Methods. 2010;61(2):171-7.
Towbin H, Gordon J. Immunoblotting and dot immunobinding—current status and outlook. J Immunol Methods. 1984;72(2):313-40.
Mahmood T, Yang P-C. Western blot: Technique, theory, and trouble shooting. N Am J Med Sci. 2012;4(9):429.
Cunningham C, Campion S, Teeling J, Felton L, Perry V. The sickness behavior and CNS inflammatory mediator profile induced by systemic challenge of mice with synthetic double-stranded RNA (poly I: C). Brain Behav Immun. 2007;21(4):490-502.
Boksa P. Effects of prenatal infection on brain development and behavior: a review of findings from animal models. Brain Behav Immun. 2010;24(6):881-97.
Warner-Schmidt JL, Duman RS. Hippocampal neurogenesis: opposing effects of stress and antidepressant treatment. Hippocampus. 2006;16(3):239-49.
Tsankova NM, Berton O, Renthal W, Kumar A, Neve RL, Nestler EJ. Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action. Nat Neurosci. 2006;9(4):519-25.
Covington III HE, Vialou VF, LaPlant Q, Ohnishi YN, Nestler EJ. Hippocampal-dependent antidepressant-like activity of histone deacetylase inhibition. Neurosci Lett. 2011;493(3):122-6.
Miller L, Foradori CD, Lalmansingh AS, Sharma D, Handa RJ, Uht RM. Histone deacetylase 1 (HDAC1) participates in the down-regulation of corticotropin releasing hormone gene (crh) expression. Physiol Behav. 2011;104(2):312-20.
Bahari-Javan S, Maddalena A, Kerimoglu C, Wittnam J, Held T, Bähr M, et al. HDAC1 regulates fear extinction in mice. J Neurosci. 2012;32(15):5062-73.
Covington HE, Maze I, LaPlant QC, Vialou VF, Ohnishi YN, Berton O, et al. Antidepressant actions of histonedeacetylase inhibitors. J Neurosci. 2009;29(37):11451-60.
Kim M-S, Akhtar MW, Adachi M, Mahgoub M, Bassel-Duby R, Kavalali ET, et al. An essential role for histone deacetylase 4 in synaptic plasticity and memory formation. J Neurosci. 2012;32(32):10879-86.
Jochems J, Boulden J, Lee BG, Blendy JA, Jarpe M, Mazitschek R, et al. Antidepressant-Like Properties of Novel HDAC6-Selective Inhibitors with Improved Brain Bioavailability. Neuropsychopharmacology. 2013.